Maxcyte (MXCT) FCF Margin (2020 - 2026)

Maxcyte (MXCT) has reported FCF Margin for 7 consecutive years, with 42.43% the latest figure, recorded in Q2 2026.

• On a quarterly basis, FCF Margin rose 8025.0% year-over-year to 42.43% in Q2 2026; TTM through Jun 2026 was 71.04%, a 3598.0% increase from a year earlier, with the FY2025 full-year figure at 109.54%, down 3379.0% from the prior year.
• FCF Margin was 42.43% for Q2 2026 at Maxcyte, up from 85.96% in the prior quarter.
• Over five years, FCF Margin peaked at 0.42% in Q4 2023 and troughed at 144.99% in Q1 2025.
• A 5-year average of 80.38% and a median of 84.81% in 2022 frame the typical range for FCF Margin.
• Across the five-year window, FCF Margin slumped 9208 bps in 2024 and surged 8025 bps in 2026, its largest moves.
• Over 5 years, FCF Margin stood at 66.66% in 2022, then jumped by 101 bps to 0.42% in 2023, then sank by 21855 bps to 91.66% in 2024, then surged by 56 bps to 40.0% in 2025, then decreased by 6 bps to 42.43% in 2026.
• The last three FCF Margin figures came in at 42.43% (Q2 2026), 85.96% (Q1 2026), and 40.0% (Q4 2025), per Business Quant data.